PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 31, 2026Blood1 citations

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71

View Full Paper
ASAndre Maurice SmallSPSiddharth M. PatelRGRobert P Giugliano

Key Points

  • This analysis aims to determine how prior oral anticoagulation experience influences bleeding risk in patients treated with the factor XI inhibitor abelacimab.
  • Prespecified analysis from AZALEA-TIMI 71 trial
  • Patients with atrial fibrillation
  • Assessment of bleeding risk associated with abelacimab in relation to prior anticoagulation experience
  • Abelacimab reduced bleeding consistently across different prior anticoagulation experiences.
  • Greater absolute benefit noted among patients who were OAC-naïve.
  • NCT04755283 for trial registration.

Abstract

This prespecified analysis from AZALEA-TIMI 71 demonstrated that prior oral anticoagulation (OAC) experience modifies bleeding risk in atrial fibrillation. The factor XI inhibitor abelacimab consistently reduced bleeding irrespective of prior OAC experience, with potentially greater absolute benefit among OAC-naïve patients. CT# NCT04755283

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Small et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd2845783ba022b6fdf34https://doi.org/10.1182/blood.2026033829
Ask AI
Helpful
Bookmark
Share
View Full Paper